InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
5
T+90 hit rate
80%
T+90 mean return
+19.2%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Connaughton Bernadette, Director. Officer active across 2 companies, notably Halozyme Therapeutics, INC.. Aggregated, 17 filings have been recorded. Breakdown: 0 buy · 5 sells. Total volume traded: €509k. Activity tracked since 5 May 2021. The latest transaction was filed on 1 June 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations17 total
1,625 shares@ US$66.210.0011% mcap18.2% of flowCommon StockSEC:0001159036-26-000072:0
1,625 shares@ US$63.480.0011% mcap21.1% of flowCommon StockSEC:0001159036-26-000055:0
1,625 shares@ US$63.480.0011% mcap21.1% of flowCommon StockSEC:0001159036-26-000055
2,000 shares@ US$70.2528.9% of flowCommon StockSEC:0001159036-26-000006
2,000 shares@ US$70.250.0015% mcap28.9% of flowCommon StockSEC:0001159036-26-000006:0
4,165 shares0Common StockSEC:0001415889-25-011767:0
6,501 shares0Common StockSEC:0001415889-24-011679:0
9,915 shares@ US$43.00100.0% of flowClass A Common StockSEC:0001209191-23-050772:0
4,863 shares0Class A Common StockSEC:0001209191-23-032940:0
8,065 shares0Common StockSEC:0001415889-23-007688:0
5,998 shares0Common StockSEC:0001415889-22-011511:0
2,839 shares0Class A Common StockSEC:0001209191-22-032624:0
6,206 shares0Restricted Stock UnitsSEC:0001179110-22-002907:0
2,364 shares0Class A Common StockSEC:0001209191-21-032806
2,364 shares0Class A Common StockSEC:0001209191-21-032806:0
5,230 sharesRestricted Stock UnitsSEC:0001179110-21-004970
5,230 shares0Restricted Stock UnitsSEC:0001179110-21-004970:0
17 of 17 declarations
About Connaughton Bernadette
Bernadette Connaughton is a Director at Halozyme Therapeutics, Inc. and Syneos Health, Inc. She contributes to the governance of both companies and strategic decision-making. Bernadette brings her expertise in biotechnology to help guide growth initiatives.
